BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26894974)

  • 21. De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling.
    Del Vecchio CA; Feng Y; Sokol ES; Tillman EJ; Sanduja S; Reinhardt F; Gupta PB
    PLoS Biol; 2014 Sep; 12(9):e1001945. PubMed ID: 25203443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. lncMat2B regulated by severe hypoxia induces cisplatin resistance by increasing DNA damage repair and tumor-initiating population in breast cancer cells.
    García-Venzor A; Mandujano-Tinoco EA; Ruiz-Silvestre A; Sánchez JM; Lizarraga F; Zampedri C; Melendez-Zajgla J; Maldonado V
    Carcinogenesis; 2020 Nov; 41(11):1485-1497. PubMed ID: 32710610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation.
    Noman ASM; Parag RR; Rashid MI; Islam S; Rahman MZ; Chowdhury AA; Sultana A; Jerin C; Siddiqua A; Rahman L; Nayeem J; Akther S; Baidya S; Shil RK; Rahman M; Shirin A; Mahmud R; Hossain SMI; Sumi SA; Chowdhury A; Basher SB; Hasan A; Bithy S; Aklima J; Chowdhury N; Hasan MN; Banu T; Chowdhury S; Hossain MM; Yeger H; Farhat WA; Islam SS
    Cell Death Dis; 2020 Aug; 11(8):663. PubMed ID: 32814771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance.
    Mirzaei S; Mohammadi AT; Gholami MH; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Makvandi P; Samec M; Liskova A; Kubatka P; Nabavi N; Aref AR; Ashrafizadeh M; Khan H; Najafi M
    Pharmacol Res; 2021 May; 167():105575. PubMed ID: 33771701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear factor erythroid 2-related factor 2 promotes radioresistance by regulating glutamate-cysteine ligase modifier subunit and its unique immunoinvasive pattern.
    Xue Z; Nuerrula Y; Sitiwaerdi Y; Eli M
    Biomol Biomed; 2024 May; 24(3):545-559. PubMed ID: 38340316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
    Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
    Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
    Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lico A Enhances Nrf2-Mediated Defense Mechanisms against t-BHP-Induced Oxidative Stress and Cell Death via Akt and ERK Activation in RAW 264.7 Cells.
    Lv H; Ren H; Wang L; Chen W; Ci X
    Oxid Med Cell Longev; 2015; 2015():709845. PubMed ID: 26576227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
    Chian S; Thapa R; Chi Z; Wang XJ; Tang X
    Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetramethylpyrazine inhibits CoCl2 -induced neurotoxicity through enhancement of Nrf2/GCLc/GSH and suppression of HIF1α/NOX2/ROS pathways.
    Guan D; Su Y; Li Y; Wu C; Meng Y; Peng X; Cui Y
    J Neurochem; 2015 Aug; 134(3):551-65. PubMed ID: 25952107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
    Kim EH; Jang H; Shin D; Baek SH; Roh JL
    Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
    Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
    Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
    Kim EH; Jang H; Roh JL
    Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
    Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
    Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents.
    Samatiwat P; Prawan A; Senggunprai L; Kukongviriyapan U; Kukongviriyapan V
    Tumour Biol; 2016 Aug; 37(8):11495-507. PubMed ID: 27015836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway].
    Wang LJ; Wang SG; Deng TX
    Sheng Li Xue Bao; 2018 Aug; 70(4):397-405. PubMed ID: 30112565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
    Kim EH; Baek S; Shin D; Lee J; Roh JL
    Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway.
    Shim GS; Manandhar S; Shin DH; Kim TH; Kwak MK
    Free Radic Biol Med; 2009 Dec; 47(11):1619-31. PubMed ID: 19751820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection by chrysin, apigenin, and luteolin against oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase 1 and glutamate cysteine ligase in rat primary hepatocytes.
    Huang CS; Lii CK; Lin AH; Yeh YW; Yao HT; Li CC; Wang TS; Chen HW
    Arch Toxicol; 2013 Jan; 87(1):167-78. PubMed ID: 22864849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.
    Shi L; Chen ZG; Wu LL; Zheng JJ; Yang JR; Chen XF; Chen ZQ; Liu CL; Chi SY; Zheng JY; Huang HX; Lin XY; Zheng F
    Asian Pac J Cancer Prev; 2014; 15(23):10439-44. PubMed ID: 25556489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.